ClinicalTrials.gg
RecruitingNCT04566380Updated Oct 14, 2026

ONO-4538 Phase II Rollover Study (ONO-4538-98)

A Phase 2 interventional study of ONO-4538 and oxaliplatin in Pan-tumor, sponsored by Ono Pharmaceutical Co., Ltd.. Recruiting at 44 sites in 3 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by Ono Pharmaceutical Co., Ltd. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2020; still recruiting 6 years 2 months later.
Updated Oct 14, 2026Site recruiting status changedPrimary completion moved+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
70
Allocation
Non-randomized
Ages
16 Years and older
Sex
All
01

Study summary

This study is intended to confirm the long-term safety of ONO-4538 in pan-tumor participants being treated with ONO-4538 monotherapy or in Combination with Other Therapies in clinical trials.

02

Conditions studied

  • Pan-tumor
03

In context

Lead sponsor

Ono Pharmaceutical Co., Ltd. is the lead sponsor of 49 studies on the registry; 18 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant who is being treated with ONO-4538 as monotherapy or in Combination with Other Therapies in clinical trials
  2. Participant who is eligible for ONO-4538 monotherapy or in combination with other therapies as per the clinical trials, and/or investigator-assessed clinical benefit

Exclusion criteria

Exclusion Criteria:

  1. Participant judged to be incapable of providing consent for reasons such as concurrent dementia
  2. Participant judged by the investigator to be inappropriate as participants of this study
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    ONO-4538 Monotherapy cohort

    480 mg of ONO-4538 IV Q4W or 240 mg of ONO-4538 IV Q2W per the investigator's choice

    Drug: ONO-4538

  • Experimental
    Combination therapy cohort

    ONO-4538 at 360 mg IV Q3W or 480 mg IV Q4W, and Combination therapies (S-1 + Oxaliplatin \[SOX\] therapy , Capecitabine + Oxaliplatin \[CapeOX\] therapy , Bevacizumab, Temozolomide, Ipilimumab + SOX therapy, Ipilimumab + CapeOX therapy or ONO-7703) selected by the principal investigator or subinvestigator in the Parent Study will be continued in this study.

    Drug: ONO-4538 · Drug: oxaliplatin · Drug: S-1 · Drug: capecitabine · Drug: bevacizumab · Drug: temozolomide · Drug: Ipilimumab · Drug: ONO-7703

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events (Aes)

    (non)

    Time frame: From Day 1 up to 28 days after the end of the treatment phase

07

Study locations

30 of 44 sites recruiting
  • Chiba Clinical Site2
    Chiba, Chiba, Japan
    Completed

    Not enrolling at this site — choose another above.

  • Chiba Clinical Site1
    Kashiwa, Chiba, Japan
    Completed

    Not enrolling at this site — choose another above.

  • Ehime Clinical Site1
    Matsuyama, Ehime, Japan
    Completed

    Not enrolling at this site — choose another above.

  • Fukuoka Clinical Site2
    Fukuoka, Fukuoka, Japan
    Completed

    Not enrolling at this site — choose another above.

  • Fukuoka Clinical Site3
    Fukuoka, Fukuoka, Japan
    Completed

    Not enrolling at this site — choose another above.

  • Fukuoka Clinical Site1
    Kurume, Fukuoka, Japan
    Completed

    Not enrolling at this site — choose another above.

  • Hiroshima Clinical Site1
    Hiroshima, Hiroshima, Japan
    Recruiting
  • Hokkaido Clinical Site1
    Sapporo, Hokkaido, Japan
    Recruiting
  • Hyogo Clinical Site1
    Akashi, Hyōgo, Japan
    Completed

    Not enrolling at this site — choose another above.

  • Kanagawa Clinical Site1
    Yokohama, Kanagawa, Japan
    Completed

    Not enrolling at this site — choose another above.

  • Kyoto Clinical Site1
    Kyoto, Kyoto, Japan
    Recruiting
  • Oita Clinical Site1
    Yufu, Oita Prefecture, Japan
    Recruiting
  • Okayama Clinical Site1
    Okayama, Okayama-ken, Japan
    Recruiting
  • Osaka Clinical Site2
    Osaka, Osaka, Japan
    Recruiting
  • Osaka Clinical Site1
    Suita, Osaka, Japan
    Recruiting
  • Osaka Clinical Site3
    Takatsuki, Osaka, Japan
    Recruiting
  • Saitama Clinical Site1
    Hidaka, Saitama, Japan
    Recruiting
  • Saitama Clinical Site2
    Kitaadachi-gun, Saitama, Japan
    Completed

    Not enrolling at this site — choose another above.

  • Tokyo Clinical Site3
    Bunkyo-ku, Tokyo, Japan
    Recruiting
  • Tokyo Clinical Site2
    Chuo-ku, Tokyo, Japan
    Recruiting
  • Tokyo Clinical Site1
    Koto-ku, Tokyo, Japan
    Completed

    Not enrolling at this site — choose another above.

  • Tokyo Clinical Site5
    Koto-Ku, Tokyo, Japan
    Recruiting
  • Tokyo Clinical Site4
    Shinjuku-ku, Tokyo, Japan
    Recruiting
  • Daegu Clinical Site1
    Daegu, South Korea, South Korea
    Recruiting
  • Daegu Clinical Site2
    Daegu, South Korea
    Recruiting
  • Daegu Clinical Site3
    Daegu, South Korea
    Recruiting
  • Gyeonggi-do Clinical site1
    Gyeonggi-do, South Korea
    Recruiting
  • Hwasun Clinical Site1
    Hwasun, South Korea
    Recruiting
  • Incheon Clinical Site1
    Incheon, South Korea
    Completed

    Not enrolling at this site — choose another above.

  • Seoul Clinical Site1
    Seoul, South Korea
    Recruiting
  • Seoul Clinical Site2
    Seoul, South Korea
    Completed

    Not enrolling at this site — choose another above.

  • Seoul Clinical Site3
    Seoul, South Korea
    Recruiting
  • Seoul Clinical Site4
    Seoul, South Korea
    Recruiting
  • Seoul Clinical Site5
    Seoul, South Korea
    Recruiting
  • Seoul Clinical Site6
    Seoul, South Korea
    Recruiting
  • Suwon Clinical Site1
    Suwon, South Korea
    Recruiting
  • Taoyuan Clinical Site1
    Taoyuan, Taiwan, Taiwan
    Recruiting
  • Kaohsiung Clinical Site1
    Kaohsiung City, Taiwan
    Completed

    Not enrolling at this site — choose another above.

  • Kaohsiung Clinical Site2
    Kaohsiung City, Taiwan
    Completed

    Not enrolling at this site — choose another above.

  • New Taipei City Clinical Site1
    New Taipei City, Taiwan
    Recruiting
  • Tainan Clinical Site1
    Tainan, Taiwan
    Recruiting
  • Tainan Clinical Site2
    Tainan, Taiwan
    Recruiting
  • Taipei Clinical Site1
    Taipei, Taiwan
    Recruiting
  • Taipei Clinical Site2
    Taipei, Taiwan
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Sep 2020 (actual). Primary completion is estimated for Dec 2027, 87 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 14, 2026: primary completion Dec 2026 → Dec 2027 and completion Dec 2026 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2020
First posted
Sep 28, 2020
StartActual
Sep 10, 2020
Primary completionEst.
Dec 31, 2027was Dec 2026
CompletionEst.
Dec 31, 2027was Dec 2026
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
19 sites added, 13 sites removed. 5 sites changed recruiting status (5 now completed)
Show 5 sites
  • Chiba Clinical Site1 · Kashiwa, JapanRecruiting→Completed
  • Fukuoka Clinical Site1 · Kurume, JapanRecruiting→Completed
  • Kanagawa Clinical Site1 · Yokohama, JapanRecruiting→Completed
  • Saitama Clinical Site2 · Kitaadachi-gun, JapanRecruiting→Completed
  • Tokyo Clinical Site1 · Koto-ku, JapanRecruiting→Completed
Show 19 added (10 Japan, 5 South Korea, 4 Taiwan)
  • Chiba Clinical Site2 · Chiba, Japan
  • Fukuoka Clinical Site2 · Fukuoka, Japan
  • Fukuoka Clinical Site3 · Fukuoka, Japan
  • Hiroshima Clinical Site1 · Hiroshima, Japan
  • Hyogo Clinical Site1 · Akashi, Japan
  • Kyoto Clinical Site1 · Kyoto, Japan
  • Oita Clinical Site1 · Yufu, Japan
  • Okayama Clinical Site1 · Okayama, Japan
  • Osaka Clinical Site2 · Osaka, Japan
  • Tokyo Clinical Site5 · Koto-Ku, Japan
  • Daegu Clinical Site1 · Daegu, South Korea
  • Daegu Clinical Site2 · Daegu, South Korea
  • Daegu Clinical Site3 · Daegu, South Korea
  • Hwasun Clinical Site1 · Hwasun, South Korea
  • Suwon Clinical Site1 · Suwon, South Korea
  • Taoyuan Clinical Site1 · Taoyuan, Taiwan
  • Kaohsiung Clinical Site1 · Kaohsiung City, Taiwan
  • Kaohsiung Clinical Site2 · Kaohsiung City, Taiwan
  • New Taipei City Clinical Site1 · New Taipei City, Taiwan
Show 13 removed
  • Hyogo Clinical Site1 · Akashi, Japan
  • Oita Clinical Site1 · Yufu, Japan
  • Chiba Clinical Site2 · Chiba, Japan
  • Fukuoka Clinical Site2 · Fukuoka, Japan
  • Fukuoka Clinical Site3 · Fukuoka, Japan
  • Hiroshima Clinical Site1 · Hiroshima, Japan
  • Kyoto Clinical Site1 · Kyoto, Japan
  • Okayama Clinical Site1 · Okayama, Japan
  • Osaka Clinical Site2 · Osaka, Japan
  • Daegu Clinical Site1 · Daegu, Korea, Republic of
  • Kaohsiung Clinical Site1 · Kaohsiung, Taiwan
  • Kaohsiung Clinical Site2 · Kaohsiung, Taiwan
  • Taoyuan Clinical Site1 · Taoyuan, Taiwan
Oct 14, 2026
Primary completion
Dec 31, 2026→Dec 31, 2027
Oct 14, 2026
Study completion
Dec 31, 2026→Dec 31, 2027
Oct 14, 2026
Enrollment
59→70
Oct 14, 2026
Interventions
Added Drug: Ipilimumab·Drug: ONO-7703
Oct 14, 2026
Sponsor
Ono Pharmaceutical Co. Ltd→Ono Pharmaceutical Co., Ltd.
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    19 sites added, 13 sites removed. 5 sites changed recruiting status (5 now completed)
    Show 5 sites
    • Chiba Clinical Site1 · Kashiwa, JapanRecruiting→Completed
    • Fukuoka Clinical Site1 · Kurume, JapanRecruiting→Completed
    • Kanagawa Clinical Site1 · Yokohama, JapanRecruiting→Completed
    • Saitama Clinical Site2 · Kitaadachi-gun, JapanRecruiting→Completed
    • Tokyo Clinical Site1 · Koto-ku, JapanRecruiting→Completed
    Show 19 added (10 Japan, 5 South Korea, 4 Taiwan)
    • Chiba Clinical Site2 · Chiba, Japan
    • Fukuoka Clinical Site2 · Fukuoka, Japan
    • Fukuoka Clinical Site3 · Fukuoka, Japan
    • Hiroshima Clinical Site1 · Hiroshima, Japan
    • Hyogo Clinical Site1 · Akashi, Japan
    • Kyoto Clinical Site1 · Kyoto, Japan
    • Oita Clinical Site1 · Yufu, Japan
    • Okayama Clinical Site1 · Okayama, Japan
    • Osaka Clinical Site2 · Osaka, Japan
    • Tokyo Clinical Site5 · Koto-Ku, Japan
    • Daegu Clinical Site1 · Daegu, South Korea
    • Daegu Clinical Site2 · Daegu, South Korea
    • Daegu Clinical Site3 · Daegu, South Korea
    • Hwasun Clinical Site1 · Hwasun, South Korea
    • Suwon Clinical Site1 · Suwon, South Korea
    • Taoyuan Clinical Site1 · Taoyuan, Taiwan
    • Kaohsiung Clinical Site1 · Kaohsiung City, Taiwan
    • Kaohsiung Clinical Site2 · Kaohsiung City, Taiwan
    • New Taipei City Clinical Site1 · New Taipei City, Taiwan
    Show 13 removed
    • Hyogo Clinical Site1 · Akashi, Japan
    • Oita Clinical Site1 · Yufu, Japan
    • Chiba Clinical Site2 · Chiba, Japan
    • Fukuoka Clinical Site2 · Fukuoka, Japan
    • Fukuoka Clinical Site3 · Fukuoka, Japan
    • Hiroshima Clinical Site1 · Hiroshima, Japan
    • Kyoto Clinical Site1 · Kyoto, Japan
    • Okayama Clinical Site1 · Okayama, Japan
    • Osaka Clinical Site2 · Osaka, Japan
    • Daegu Clinical Site1 · Daegu, Korea, Republic of
    • Kaohsiung Clinical Site1 · Kaohsiung, Taiwan
    • Kaohsiung Clinical Site2 · Kaohsiung, Taiwan
    • Taoyuan Clinical Site1 · Taoyuan, Taiwan
    Primary completion Dec 31, 2026→Dec 31, 2027
    Study completion Dec 31, 2026→Dec 31, 2027
    Enrollment 59→70
    Interventions Added Drug: Ipilimumab·Drug: ONO-7703
    Sponsor Ono Pharmaceutical Co. Ltd→Ono Pharmaceutical Co., Ltd.
    + 4 other changes: identifiers, verification date, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04566380
Responsible party
Sponsor
First posted
Sep 28, 2020
Start date
Sep 10, 2020
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Oct 14, 2026

Study contacts

North America Clinical Trial Support Desk
Contact
clinical_trial@ono-pharma.com
+18665877745(Toll-Free)
International Clinical Trial Support Desk
Contact
clinical_trial@ono-pharma.com
+17162141777(Standard)
Project Leader
study director · Ono Pharmaceutical Co., Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nivolumab

Start the discussion